Haemonetics Reports Adjusted Earnings per Share of $0.74 for Q1 of Fiscal 11 Company Affirms Full Year Guidance

News provided by

Haemonetics Corporation

Aug 02, 2010, 08:00 ET

BRAINTREE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) today reported GAAP net revenues of $163 million, up 6%, net income of $18 million, down 1%, and earnings per share of $0.70, up 1%.  Excluding transformation costs in fiscal 11, adjusted first quarter net income was $19 million, up 5%, and adjusted earnings per share was $0.74, up 7%. In constant currency, revenue was up 8%, adjusted net income was up 30% and adjusted earnings per share were up 32%. (1)

As expected, the quarterly growth in both revenue and net income were adversely impacted by trends in both foreign currency hedge rates and Q1 plasma growth rates. The Company expects the currency headwinds to moderate and plasma growth to accelerate throughout the remainder of the year. The adverse impact of currency on net income growth in the first quarter was $2.9 million. Based on currency hedges in place for the remainder of the year, the full year adverse impact of currency on net income growth is currently expected to moderate to $1.3 million. Plasma, which is expected to grow 6-8% for the full year, declined 5% in the quarter when compared to particularly strong growth in Q1 of fiscal 10. (1)

In addition to revenue and earnings growth, Haemonetics reported adjusted gross margin of 53%, up 70 basis points, and adjusted operating margin of 15.9%, down 70 basis points from the fiscal 10 finish. Annual operating income guidance, which reflects full year hedged currency trends, calls for double digit operating income growth for the year.  The Company managed adjusted operating expenses to $60.5 million, up $3.9 million from levels in Q1 of fiscal 10. Incremental spending is associated with the Company’s recent acquisitions, ($3 million) and its automated whole blood and Arryx blood typing initiatives. (1)

Brian Concannon, Haemonetics’ President and CEO, said, “We are off to a solid start in fiscal 11 posting top and bottom line growth while dealing with anticipated Q1 headwinds in plasma growth rates and currency. As currency headwinds moderate and Plasma accelerates we will see favorable trends in the last three quarters that give us confidence about achieving our commitments for the year.”

The Company affirmed its full year guidance of 9-12% revenue growth, adjusted operating income growth of 11-14%, and adjusted earnings per share in a range of $3.15 to $3.25.(1)

STRATEGIC AND SEGMENT GROWTH HIGHLIGHTS

Haemonetics continues to make progress expanding its business.  The Company reported the following highlights:

  • A recently signed agreement with Consorta, a Group Purchasing Organization which represents 11 Integrated Delivery Network shareholders with 260 acute care hospitals and an additional 270 affiliated acute care facilities, to provide IMPACT™ Online, the Company’s web based portal that enables blood management analysis and decision making. The agreement will allow Haemonetics to target specific members of Consorta’s network that will leverage the scalability and simplicity of IMPACT Online as a key component of the hospitals’ approach to blood management.
  • Enabled by Haemonetics BloodTrack® HaemoSafe, the Puget Sound Blood Center and Overlake Hospital Medical Center announced their partnership to launch a new blood distribution system.  This is a unique collaboration between a blood center and hospital, designed to improve the availability and access to blood components.
  • 24 new IMPACT customers in Q1 fiscal 11 bringing the total number of IMPACT customers to 90, driving acceleration in key product lines evidenced by a 24% Q1 growth rate for TEG® disposables.
  • The Global Med acquisition integration is proceeding well against the planned schedule and budget.
  • During Q1, Haemonetics completed its planned $50 million share repurchase acquiring approximately 900,000 shares.

Mr. Concannon added “We have also made excellent progress against our goals for blood management with 90 IMPACT accounts by the end of the first quarter and more recently the signing of a system wide agreement for blood management with Consorta. Our value proposition is taking hold in the markets we serve and represents a strong catalyst for growth this fiscal year. Combine continued growth from IMPACT selling, with currency moderation and Plasma acceleration, and you can see why I remain very confident about achieving our current guidance”

As noted, Haemonetics’ first quarter fiscal 11 reported revenues were $163 million, up 6%.  Excluding the effects of currency, revenues grew 8%.  Reported revenues break down as follows:

Plasma disposables revenue was $55.9 million for the quarter, down 5%.  Haemonetics’ plasma business declined in the first quarter when compared to a strong Q1 of fiscal 10 as anticipated. Haemonetics expects its plasma business to return to low single digit growth in Q2, ramping to low double digit growth in the second half of the year.

Platelet disposables revenue was $36.3 million for the quarter, up 6%.  The platelet business benefited from strong sales in Asia and a recovery in our distribution markets in Europe and Latin America.

Red cell disposables revenue was $11.3 million for the quarter, down 4%.  Revenue declined due to decreased demand for red cells as a result of declining demand for blood.

Surgical disposables revenue was $16.4 million for the quarter, down 6%.  The surgical business was adversely impacted by trends in currency spot rates.

OrthoPAT® orthopedic perioperative autotransfusion system disposables revenue was $9 million for the quarter, up 4%.  The Company continues to make progress advancing OrthoPAT system sales in IMPACT accounts.

Diagnostic disposables revenue was $4.7 million for the quarter, up 24%. Revenues related to the TEG Thrombelastograph® Hemostasis Analyzer business are accelerating driven by the Company’s IMPACT accounts.

Software Solutions revenue was $16.5 million for the quarter, up 95%.  Software Solutions growth was primarily impacted by our Global Med acquisition. Underlying organic growth of our core software business was 9% in the first quarter.

Equipment revenue was $13 million for the quarter, up 20%.  Equipment growth was impacted by the SEBRA® acquisition. Organic equipment growth in the quarter was 5%.

Haemonetics reported growth in all geographies for the quarter, with North American sales up 6%, European sales up 2%, Japanese sales up 2%, and Asian sales up 30%.

CONFERENCE CALL

Haemonetics will host a webcast on Monday, August 2nd at 10:00 am Eastern to discuss these results.  Interested parties can participate at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=3186588

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission.  The foregoing list should not be construed as exhaustive.  The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. 

(1)  A reconciliation of GAAP to adjusted and constant currency financial results is included at the end of the financial sections of this press release as well as on the web at http://www.haemonetics.com/site/content/investor/investor.asp.  In the first quarter of fiscal 11, Haemonetics incurred $1.7 million in pre-tax restructuring costs.  Haemonetics incurred no restructuring costs in the first quarter of fiscal 10.

Haemonetics Corporation Financial Summary

(Unaudited data in thousands, except per share data)

Consolidated Statements of Income for the First Quarter FY11




7/3/2010
As Reported

6/27/2009
As Reported

% Inc/(Dec)
vs Prior Year

NET REVENUES

$163,039

$154,087

5.8%

Gross profit

86,463

82,943

4.2%









R&D

7,920

6,777

16.9%

S,G&A

54,354

49,839

9.1%

Operating expenses

62,274

56,616

10.0%








Operating income


24,189

26,327

(8.1%)

Interest expense

(153)

(214)

(28.5%)

Interest income

102

157

(35.0%)

Other (expense)/income, net

237

(335)

(170.6%)








Income before taxes

24,375

25,935

(6.0%)








Tax expense

6,457

7,862

(17.9%)








NET INCOME

$17,918

$18,073

(0.9%)








Net income per common share





assuming dilution 

$0.70

$0.69

1.0%








Weighted average number of shares






Basic

25,140

25,658


Diluted

25,703

26,201









Profit Margins:




Inc/(Dec) vs
prior year profit
margin %

Gross profit

53.0%

53.8%

(0.8%)

R&D

4.9%

4.4%

0.5%

S,G&A

33.3%

32.3%

1.0%

Operating income

14.8%

17.1%

(2.2%)

Income before taxes

15.0%

16.8%

(1.9%)

Net income

11.0%

11.7%

(0.7%)

Revenue Analysis for the First Quarter and Year-To-Date FY11


First Quarter


7/3/2010
As Reported

6/27/2009
As Reported

% Inc/(Dec) vs
Prior Year

Revenues by geography





United States

$79,309

$75,013

5.7%

International

$83,730

$79,074

5.9%

Net revenues

$163,039

$154,087

5.8%








Disposable revenues












Plasma disposables

$55,918

$58,868

(5.0%)








Blood bank disposables





Platelet

$36,317

$34,306

5.9%

Red cell

$11,314

$11,779

(3.9%)


$47,631

$46,085

3.4%

Hospital disposables





Surgical

$16,351

$17,425

(6.2%)

OrthoPAT

$8,957

$8,584

4.3%

Diagnostics

$4,708

$3,811

23.5%


$30,016

$29,820

0.7%








Subtotal

$133,565

$134,773

(0.9%)








Software solutions

$16,453

$8,454

94.6%

Equipment & other

$13,021

$10,860

19.9%

Net revenues

$163,039

$154,087

5.8%














Consolidated Balance Sheets




Period ending


7/3/10

4/3/10





Assets


Cash & cash equivalents

$83,467

$141,562

Accounts receivable, net

114,834

118,684

Inventories, net

84,571

79,953

Other current assets

40,674

45,944

Total current assets

323,546

386,143

Net PP&E

157,365

153,298

Other assets

213,253

221,219





  Total assets

$694,164

$760,660












Period ending


7/3/10

4/3/10





Liabilities & Stockholders' Equity


S/T debt & current maturities

$6,418

$16,062

Other current liabilities

96,270

120,435

Total current liabilities

102,688

136,497

Long-term debt

4,384

4,589

Other long-term liabilities

22,136

26,450

Stockholders' equity

564,956

593,124





  Total liabilities & equity

$694,164

$760,660

Free Cash Flow Reconciliation





Three Months Ended

7/3/10

6/27/09




GAAP cash flow from operations

$13,556

$25,706




Capital expenditures

(15,224)

(21,204)

Proceeds from sale of property, plant and equipment

111

201

Net investment in property, plant and equipment

(15,113)

(21,003)




Free cash flow after transformation and deal costs

($1,557)

$4,703




Transformation and deal costs

4,058

-

Global Med employment contracts

2,122

-

6,180

-




Free cash flow before transformation and deal costs

$4,623

$4,703

Haemonetics Corporation Financial Summary

Reconciliation of Non-GAAP Measures


Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release.  A reconciliation is provided below that reconciles
each non-GAAP financial measure with the most comparable GAAP measure.  The presentation of non-GAAP financial measures should not be considered
in isolation from, or as a substitute for, the most directly comparable GAAP measures.  There are material limitations to the usefulness of non-GAAP
measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results.  
Performance targets for management are established based upon these non-GAAP measures.  In the reconciliations below, we have removed restructuring
and deal integration costs from our GAAP expenses.  Our restructuring is related to the integration of Global Med Technologies and the repositioning of our
sales force.  We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our
core operations.

Non-GAAP Gross Profit
The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation.  We
establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP S,G&A and Non-GAAP Operating Expenses
The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when
we are not transforming our business or completing an acquisition of in-process research and development.  We establish our budgets, forecasts, and
performance targets excluding these costs.

Non-GAAP Operating Income and Non-GAAP Income before Income Taxes
The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business
transformation.  We establish our budgets, forecasts, and performance targets on this basis.

Non-GAAP Net Income and Earnings per Share
The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our
business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.


Reconciliation of Non-GAAP Measures for the First Quarter of FY11 and FY10



07/03/10

06/27/09

Non-GAAP gross profit



GAAP gross profit

$86,463

$82,943

Restructuring costs

-

-

Non-GAAP gross profit

$86,463

$82,943










Non-GAAP S,G&A



GAAP S,G&A

$54,354

$49,839

Restructuring and deal integration costs

(1,743)

-

Non-GAAP S,G&A

$52,611

$49,839










Non-GAAP operating expenses



GAAP operating expenses

$62,274

$56,616

Restructuring and deal integration costs

(1,743)

-

Non-GAAP operating expenses

$60,531

$56,616










Non-GAAP operating income





GAAP operating income

$24,189

$26,327

Restructuring and deal integration costs

1,743

-

Non-GAAP operating income


$25,932

$26,327










Non-GAAP income before taxes



GAAP income before taxes

$24,375

$25,935

Restructuring and deal integration costs

1,743

0

Non-GAAP income before taxes

$26,118

$25,935










Non-GAAP net income



GAAP net income

$17,918

$18,073

Restructuring and deal integration costs

1,743

0

Tax benefit associated with non-GAAP items

(600)

-

Non-GAAP net income

$19,061

$18,073










Non-GAAP net income per common share assuming dilution



GAAP net income per common share assuming dilution

$0.70

$0.69

Non-GAAP items after tax per common share assuming dilution

0.04

-

Non-GAAP net income per common share assuming dilution

$0.74

$0.69





Presented below are additional Constant Currency performance measures.  We measure different components of our business at constant currency.  
We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange
rates.  These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of $1.20 per Euro, and 110 Yen
to the $1.00.  They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements
in our Form 10-K.  










Non-GAAP revenues



GAAP revenue

$163,039

$154,087

Foreign currency effects

(6,683)

(9,600)

Non-GAAP revenue - constant currency

$156,356

$144,487





Non-GAAP net income



Non-GAAP net income, adjusted for restructuring and deal integration costs

$19,061

$18,073

Foreign currency effects

(3,251)

(7,516)

Income tax associated with foreign currency effects

878

2,277

Non-GAAP net income - constant currency

$16,688

$12,834





Non-GAAP net income per common share assuming dilution



Non-GAAP net income per common share assuming dilution, adjusted for restructuring and deal integration costs

$0.74

$0.69

Foreign currency effects after tax per common share assuming dilution

(0.09)

(0.20)

Non-GAAP net income per common share assuming dilution - constant currency

$0.65

$0.49

CONTACT:

Bryanne Salmon

Tel. (781) 356-9613

[email protected]

SOURCE Haemonetics Corporation

21%

more press release views with 
Request a Demo

Also from this source

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are...
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on...
More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Earnings

Earnings

Earnings

Earnings

News Releases in Similar Topics